Saltar al contenido
Merck
Todas las fotos(1)

Documentos

1134153

USP

Cilostazol

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C20H27N5O2
Número de CAS:
73963-72-1
Peso molecular:
369.46
MDL number:
MFCD00866780
UNSPSC Code:
41116107
PubChem Substance ID:
329749401
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

cilostazol

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

InChI key

RRGUKTPIGVIEKM-UHFFFAOYSA-N

Gene Information

human ... PDE3A(5139)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

Cilostazol is a potent cyclic nucleotide phosphodiesterase inhibitor. It is mainly used as antiplatelet agent.

Application

Cilostazol USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Cilostazol Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

1134164

Cilostazol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1134175

Cilostazol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1134186

Cilostazol Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1503

Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1653

Cilostazol Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1676

Cilostazol Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2855

Cilostazol Related Compound A, pharmaceutical secondary standard, certified reference material

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361d

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

S Takahashi et al.
Journal of cardiovascular pharmacology, 20(6), 900-906 (1992-12-01)
Cilostazol, a cyclic AMP phosphodiesterase inhibitor, has been used as an antiplatelet agent. In the present study, we investigated the in vitro effect of cilostazol on DNA synthesis in rat aortic arterial smooth muscle cells (SMCs) in culture stimulated with
James J Dinicolantonio et al.
The American journal of cardiology, 112(8), 1230-1234 (2013-07-06)
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has shown promise for the secondary prevention of stroke. A systematic review and meta-analysis of randomized controlled trials using Ovid
Kelly C Rogers et al.
The Annals of pharmacotherapy, 46(6), 839-850 (2012-06-07)
To evaluate the addition of cilostazol to standard dual antiplatelet therapy (DAT) with aspirin and clopidogrel in patients receiving coronary stenting. Relevant information was identified through a search of MEDLINE (1966-November 2011), International Pharmaceutical Abstracts (1960-2011), and Cochrane Databases (publications
Natnicha Kanlop et al.
Journal of cardiovascular medicine (Hagerstown, Md.), 12(2), 88-95 (2011-01-05)
Cilostazol is a selective phosphodiesterase 3 (PDE3) inhibitor approved by the Food and Drug Administration for treatment of intermittent claudication. It has also been used in bradyarrhythmic patients to increase heart rates. Recently, cilostazol has been shown to prevent ventricular
Eun-Seok Shin et al.
Heart (British Cardiac Society), 100(19), 1531-1536 (2014-06-18)
We conducted a randomised, double blind, placebo controlled trial to assess the efficacy and safety of cilostazol, a selective inhibitor of phosphodiesterase 3, in patients with vasospastic angina (VSA). Cilostazol has been shown to induce vascular dilatation, but its efficacy
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico